Angiotensin II is under clinical development by Platform Therapeutics and currently in Phase I for Muscle Spasm. According to GlobalData, Phase I drugs for Muscle Spasm does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Angiotensin II LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Angiotensin II overview
PTX-501 is under development for the prevention of muscle cramps in dialysis patients and prevention of cardiac injury. PTX-501 is a formulation of angiotensin II, an 8 amino acid, endogenous peptide. It targets type 1 angiotensin II receptor.
Platform Therapeutics overview
Platform Therapeutics is a clinical-stage life-science company that focuses on developing therapies to mitigate the toxic effects of chemotherapy and alleviate muscle cramps during dialysis. The company is headquartered in Andover, Massachusetts, the US.
For a complete picture of Angiotensin II’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.